<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>TITLE</title></head><body><div><p style="margin:0pt"><span style="font-family:'Arial (W1)'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 20pt; page-break-after:avoid; text-align:center"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written evidence submitted by the Wellcome Trust (RAD002)</span></p><p style="margin:0pt 0pt 12pt; page-break-after:avoid; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Key points</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; font-weight:normal; line-height:12pt; margin:0pt 0pt 12pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">A long-term, coordinated and stable approach across Government is essential to ensure the most effective and efficient investment in science.  </span></li><li style="font-family:Symbol; font-size:11pt; font-weight:normal; line-height:12pt; margin:0pt 0pt 12pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The UK needs a strategic and long-term approach to capital investment, and the Government must also ensure suffi</span><span style="font-family:'Times New Roman'; font-size:11pt">cient funding for operational costs to sustain </span><span style="font-family:'Times New Roman'; font-size:11pt">world-class </span><span style="font-family:'Times New Roman'; font-size:11pt">facilities.</span></li><li style="font-family:Symbol; font-size:11pt; font-weight:normal; line-height:12pt; margin:0pt 0pt 12pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The National Audit Office report does not fully recognise the unique role of charities. </span><span style="font-family:'Times New Roman'; font-size:11pt">Medical research charities are an integral part of the research and development </span><span style="font-family:'Times New Roman'; font-size:11pt">funding</span><span style="font-family:'Times New Roman'; font-size:11pt"> landscape</span><span style="font-family:'Times New Roman'; font-size:11pt">, investing over £1.2 billion </span><span style="font-family:'Times New Roman'; font-size:11pt">in 2012</span><span style="font-family:'Times New Roman'; font-size:11pt">. Their independence and flexible approach means they can support innovative research across a wide range of disease areas</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> including rarer conditions.</span></li></ul><p style="margin:0pt 0pt 12pt; page-break-after:avoid; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Introduction</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal; line-height:12pt; margin:0pt 0pt 12pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The Wellcome Trust is</span><span style="font-family:'Times New Roman'; font-size:11pt"> a global charitable foundation a</span><span style="font-family:'Times New Roman'; font-size:11pt">nd </span><span style="font-family:'Times New Roman'; font-size:11pt">the </span><span style="font-family:'Times New Roman'; font-size:11pt">UK’s largest medical charity</span><span style="font-family:'Times New Roman'; font-size:11pt">. We invest</span><span style="font-family:'Times New Roman'; font-size:11pt"> around £6</span><span style="font-family:'Times New Roman'; font-size:11pt">00 million </span><span style="font-family:'Times New Roman'; font-size:11pt">each year </span><span style="font-family:'Times New Roman'; font-size:11pt">in biomedical research</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">to realise our vision of achieving</span><span style="font-family:'Times New Roman'; font-size:11pt"> extraordinary improvements in human and animal health. </span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal; line-height:12pt; margin:0pt 0pt 12pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">We are </span><span style="font-family:'Times New Roman'; font-size:11pt">pleased to have the opportunity to respond to the </span><span style="font-family:'Times New Roman'; font-size:11pt">House of</span><span style="font-family:'Times New Roman'; font-size:11pt"> Commons Science and Technology Committee’s inquiry into research and development funding, and</span><span style="font-family:'Times New Roman'; font-size:11pt"> have included more detailed comments on the questions most relevant to the Trust in the section below.</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span></li></ol><p style="margin:0pt 0pt 12pt; page-break-after:avoid; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Inquiry</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">questions</span></p><p style="margin:0pt 0pt 12pt; page-break-after:avoid; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">General points</span></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal; line-height:12pt; margin:0pt 0pt 12pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Investment in science de</span><span style="font-family:'Times New Roman'; font-size:11pt">livers benefits to the economy, to society and to health, and is essential to underpin economic recovery and drive growth.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">In 2008, the Wellcome Trust, the Medical Research Council (MRC) and the Academy of Medical Sciences published </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Medical Research: What’</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">s it worth</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">?</span><a name="_ftnref1"></a><a href="#_ftn1">[1]</a><span style="font-family:'Times New Roman'; font-size:11pt"> which found that for every pound spent on cardiovascular and mental health research, a stream of benefits is produced equivalent to earning 39 pence and 37 pence respectively each year in perpetuity.</span><span style="font-family:'Times New Roman'; font-size:11pt"> The report also illustrated the substantial</span><span style="font-family:'Times New Roman'; font-size:11pt"> time lag between research expenditure and the realisation of health benefits, estimating this to be 17 years. A </span><span style="font-family:'Times New Roman'; font-size:11pt">follow-up study has recently been commissioned by Cancer Research UK, the Wellcome Trust, the Department of Health and the Academy of Medical S</span><span style="font-family:'Times New Roman'; font-size:11pt">ciences. This will assess the economic and health gains arising from cancer research, and the time lag between investment and achievement of health benefits.</span><span style="font-family:'Times New Roman'; font-size:11pt"> The study is expected to report in Autumn 2013.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal; line-height:12pt; margin:0pt 0pt 12pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Because of these time lags, t</span><span style="font-family:'Times New Roman'; font-size:11pt">he </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Government must ensure a </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">long-term, coordinated and stable </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">approach to </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">research and innovation</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">This should signal to potential </span><span style="font-family:'Times New Roman'; font-size:11pt">R&amp;D partners</span><span style="font-family:'Times New Roman'; font-size:11pt"> that the UK </span><span style="font-family:'Times New Roman'; font-size:11pt">is</span><span style="font-family:'Times New Roman'; font-size:11pt"> strongly supportive of science and intends to pursue an upward investment path as soon as economic c</span><span style="font-family:'Times New Roman'; font-size:11pt">onditions permit</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">The </span><span style="font-family:'Times New Roman'; font-size:11pt">Life Sciences Strategy</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">has set a transformative direction for the sector, boosting th</span><span style="font-family:'Times New Roman'; font-size:11pt">e UK’s attractiveness for R&amp;D. </span><span style="font-family:'Times New Roman'; font-size:11pt">But </span><span style="font-family:'Times New Roman'; font-size:11pt">its potential </span><span style="font-family:'Times New Roman'; font-size:11pt">will only be achieved with continued </span><span style="font-family:'Times New Roman'; font-size:11pt">Government </span><span style="font-family:'Times New Roman'; font-size:11pt">funding</span><span style="font-family:'Times New Roman'; font-size:11pt"> and commitment</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal; line-height:12pt; margin:0pt 0pt 12pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">P</span><span style="font-family:'Times New Roman'; font-size:11pt">ublic f</span><span style="font-family:'Times New Roman'; font-size:11pt">unding for science a</span><span style="font-family:'Times New Roman'; font-size:11pt">nd research </span><span style="font-family:'Times New Roman'; font-size:11pt">achieves huge leverage</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">Between 2003 and 2013, th</span><span style="font-family:'Times New Roman'; font-size:11pt">e Wellcome Trust </span><span style="font-family:'Times New Roman'; font-size:11pt">partnered with</span><span style="font-family:'Times New Roman'; font-size:11pt"> the Government to</span><span style="font-family:'Times New Roman'; font-size:11pt"> commit nearly £1.5 billion to support medical </span><span style="font-family:'Times New Roman'; font-size:11pt">research, tra</span><span style="font-family:'Times New Roman'; font-size:11pt">ining, education and innovation. </span><span style="font-family:'Times New Roman'; font-size:11pt">Between 2006 and 2011, </span><span style="font-family:'Times New Roman'; font-size:11pt">MRC </span><span style="font-family:'Times New Roman'; font-size:11pt">funding of £2.5 </span><span style="font-family:'Times New Roman'; font-size:11pt">billion </span><span style="font-family:'Times New Roman'; font-size:11pt">led to a further £1.4 billion commitment from charitable organisations</span><a name="_ftnref2"></a><a href="#_ftn2">[2]</a><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">Every </span><span style="font-family:'Times New Roman'; font-size:11pt">£1 increase in public funding for medical research stimulates up to £5 of investment by the pharmaceutical industry. </span><span style="font-family:'Times New Roman'; font-size:11pt">Sustained </span><span style="font-family:'Times New Roman'; font-size:11pt">Government support will ensure continued confidenc</span><span style="font-family:'Times New Roman'; font-size:11pt">e and investment from both charities and industry.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal; line-height:12pt; margin:0pt 0pt 12pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">World-class research </span><span style="font-family:'Times New Roman'; font-size:11pt">requires world-class facilities. The </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">UK needs a strategic and long-term approach to capital investment</span><span style="font-family:'Times New Roman'; font-size:11pt"> if it is to remain competitive. </span><span style="font-family:'Times New Roman'; font-size:11pt">The Research Council</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt"> UK Strategic Framework </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Inve</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">sting for growth: Capital Infrastructure for the 21st Century</span><a name="_ftnref3"></a><a href="#_ftn3">[3]</a><span style="font-family:'Times New Roman'; font-size:11pt"> sets out clear priorities for funding and the Government should use it as a basis for future commitments, matched with an appropriate funding profile.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal; line-height:12pt; margin:0pt 0pt 12pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In addition to capital, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">investment decisio</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">ns must take into consideration ongoing operational costs and funding requirements</span><span style="font-family:'Times New Roman'; font-size:11pt">. Where the UK already has world class facilities </span><span style="font-family:'Times New Roman'; font-size:11pt">—</span><span style="font-family:'Times New Roman'; font-size:11pt"> such as the Diamond Synchrotron </span><span style="font-family:'Times New Roman'; font-size:11pt">—</span><span style="font-family:'Times New Roman'; font-size:11pt"> the ongoing operational costs must be supported to ensure that there is maximum return o</span><span style="font-family:'Times New Roman'; font-size:11pt">n the investment.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal; line-height:12pt; margin:0pt 0pt 12pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The regulatory environment for R&amp;D must actively facilitate innovation</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">while remaining proportionate and appropriate.</span><span style="font-family:'Times New Roman'; font-size:11pt"> Not only is this necessary to ensure the UK maintains its economic competitiveness by limiting costly regulatory burdens, it is also important to maintain public trust in science. </span><span style="font-family:'Times New Roman'; font-size:11pt">In relation to medical research, t</span><span style="font-family:'Times New Roman'; font-size:11pt">he </span><span style="font-family:'Times New Roman'; font-size:11pt">establishment of the </span><span style="font-family:'Times New Roman'; font-size:11pt">Health Research A</span><span style="font-family:'Times New Roman'; font-size:11pt">uthority </span><span style="font-family:'Times New Roman'; font-size:11pt">is an important first step</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">Effective European legislation is </span><span style="font-family:'Times New Roman'; font-size:11pt">also </span><span style="font-family:'Times New Roman'; font-size:11pt">a priority</span><span style="font-family:'Times New Roman'; font-size:11pt"> given the increasingly global nature of research</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">It </span><span style="font-family:'Times New Roman'; font-size:11pt">will be particularly </span><span style="font-family:'Times New Roman'; font-size:11pt">important to ensure that </span><span style="font-family:'Times New Roman'; font-size:11pt">the </span><span style="font-family:'Times New Roman'; font-size:11pt">Clinical Trials Regulation </span><span style="font-family:'Times New Roman'; font-size:11pt">— </span><span style="font-family:'Times New Roman'; font-size:11pt">currently passing through the Europea</span><span style="font-family:'Times New Roman'; font-size:11pt">n Parliament </span><span style="font-family:'Times New Roman'; font-size:11pt">— </span><span style="font-family:'Times New Roman'; font-size:11pt">facilitates the efficient conduct of clinical trials for patient benefit.</span><a name="_GoBack"></a></li></ol><p style="line-height:12pt; margin:0pt 0pt 12pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">NAO review of R&amp;D funding</span></p><ol start="9" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal; line-height:12pt; margin:0pt 0pt 12pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">As part of</span><span style="font-family:'Times New Roman'; font-size:11pt"> its overview of research and</span><span style="font-family:'Times New Roman'; font-size:11pt"> development investment</span><span style="font-family:'Times New Roman'; font-size:11pt"> in the UK, the National Audit Office notes the cont</span><span style="font-family:'Times New Roman'; font-size:11pt">ribution of the </span><span style="font-family:'Times New Roman'; font-size:11pt">private </span><span style="font-family:'Times New Roman'; font-size:11pt">non-profit sector</span><span style="font-family:'Times New Roman'; font-size:11pt"> but does not fully</span><span style="font-family:'Times New Roman'; font-size:11pt"> recognise </span><span style="font-family:'Times New Roman'; font-size:11pt">th</span><span style="font-family:'Times New Roman'; font-size:11pt">e importance of this</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">unique </span><span style="font-family:'Times New Roman'; font-size:11pt">funding stream and the v</span><span style="font-family:'Times New Roman'; font-size:11pt">ital role </span><span style="font-family:'Times New Roman'; font-size:11pt">of</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">medical</span><span style="font-family:'Times New Roman'; font-size:11pt"> research charities as </span><span style="font-family:'Times New Roman'; font-size:11pt">independent, </span><span style="font-family:'Times New Roman'; font-size:11pt">flexible and </span><span style="font-family:'Times New Roman'; font-size:11pt">innovative funders.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">They support a wide range of </span><span style="font-family:'Times New Roman'; font-size:11pt">high quality </span><span style="font-family:'Times New Roman'; font-size:11pt">resear</span><span style="font-family:'Times New Roman'; font-size:11pt">ch </span><span style="font-family:'Times New Roman'; font-size:11pt">across disease </span><span style="font-family:'Times New Roman'; font-size:11pt">areas</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">often driven by patient demand and public donation.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal; line-height:12pt; margin:0pt 0pt 12pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In 2012, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">members of the Association of Medical Research Charities (AMRC) </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">spent more than £1.2 billion on research</span><span style="font-family:'Times New Roman'; font-size:11pt"> aimed at tackling diseases such as cancer, diabetes and heart disease, as well as r</span><span style="font-family:'Times New Roman'; font-size:11pt">arer conditions such as cystic fibrosis and motor neuron disease.</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt">Between </span><span style="font-family:'Times New Roman'; font-size:11pt">1994/95 and 2010/11, Wellcome Trust funding for </span><span style="font-family:'Times New Roman'; font-size:11pt">research and development rose from </span><span style="font-family:'Times New Roman'; font-size:11pt">£</span><span style="font-family:'Times New Roman'; font-size:11pt">161.5 million to £498.8 million; an increase of 209%.</span><span style="font-family:'Times New Roman'; font-size:11pt"> Over the past 10 years, the Trust has also c</span><span style="font-family:'Times New Roman'; font-size:11pt">ommitted £430 million in translational funding to 243 projects in more than 100 institutions and companies. These projects have already generated over £800 million in third-party finance.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal; line-height:12pt; margin:0pt 0pt 12pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">We welcome the Government’s </span><span style="font-family:'Times New Roman'; font-size:11pt">recognition of the importance of charity funding for the research base and the resulting </span><span style="font-family:'Times New Roman'; font-size:11pt">commitment to the charity research support element of QR funding. </span><span style="font-family:'Times New Roman'; font-size:11pt">This funding stream enables </span><span style="font-family:'Times New Roman'; font-size:11pt">the </span><span style="font-family:'Times New Roman'; font-size:11pt">G</span><span style="font-family:'Times New Roman'; font-size:11pt">overnment to leverage additional partnership funding from the charit</span><span style="font-family:'Times New Roman'; font-size:11pt">y sector and encourages donations by giving the public confidence that their charitable donations will be spent directly on research. </span></li></ol><p style="margin:0pt 0pt 12pt; page-break-after:avoid; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">2010 </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Spending Review</span></p><ol start="12" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal; line-height:12pt; margin:0pt 0pt 12pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The outcome for science and research in the 2010 Spending Review was better than expected, with the </span><span style="font-family:'Times New Roman'; font-size:11pt">announcement</span><span style="font-family:'Times New Roman'; font-size:11pt"> that the science and higher education research budget would receive flat funding to 2014/15</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">We </span><span style="font-family:'Times New Roman'; font-size:11pt">were </span><span style="font-family:'Times New Roman'; font-size:11pt">particularly pleased </span><span style="font-family:'Times New Roman'; font-size:11pt">ab</span><span style="font-family:'Times New Roman'; font-size:11pt">out</span><span style="font-family:'Times New Roman'; font-size:11pt"> the settlement for </span><span style="font-family:'Times New Roman'; font-size:11pt">medical rese</span><span style="font-family:'Times New Roman'; font-size:11pt">arch, </span><span style="font-family:'Times New Roman'; font-size:11pt">with a real terms increase in spending on health research through the Departme</span><span style="font-family:'Times New Roman'; font-size:11pt">nt of Health, maintenance o</span><span style="font-family:'Times New Roman'; font-size:11pt">f the</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">MRC</span><span style="font-family:'Times New Roman'; font-size:11pt"> budget in real terms, and confirmation of the Government’s capital commitment to the Francis Crick Institute.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal; line-height:12pt; margin:0pt 0pt 12pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">However, we were concerned that </span><span style="font-family:'Times New Roman'; font-size:11pt">capital was excluded from the Science Budget ring-fence in 2010 </span><span style="font-family:'Times New Roman'; font-size:11pt">and was cut </span><span style="font-family:'Times New Roman'; font-size:11pt">by 41 per cent.</span><span style="font-family:'Times New Roman'; font-size:11pt"> While additional capital </span><span style="font-family:'Times New Roman'; font-size:11pt">funding for specific projects was</span><span style="font-family:'Times New Roman'; font-size:11pt"> announced during subsequent Budgets and Autumn Statements, there is a real risk that </span><span style="font-family:'Times New Roman'; font-size:11pt">such a</span><span style="font-family:'Times New Roman'; font-size:11pt"> piecemeal </span><span style="font-family:'Times New Roman'; font-size:11pt">approach</span><span style="font-family:'Times New Roman'; font-size:11pt"> might</span><span style="font-family:'Times New Roman'; font-size:11pt"> prevent the UK from taking a strategic approach to </span><span style="font-family:'Times New Roman'; font-size:11pt">infrastructur</span><span style="font-family:'Times New Roman'; font-size:11pt">e </span><span style="font-family:'Times New Roman'; font-size:11pt">investment.</span></li></ol><p style="line-height:12pt; margin:0pt 0pt 12pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">2013 Spending Review</span></p><ol start="14" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal; line-height:12pt; margin:0pt 0pt 12pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">I</span><span style="font-family:'Times New Roman'; font-size:11pt">n 2013, the settlement for science was </span><span style="font-family:'Times New Roman'; font-size:11pt">again </span><span style="font-family:'Times New Roman'; font-size:11pt">much better than </span><span style="font-family:'Times New Roman'; font-size:11pt">expected. </span><span style="font-family:'Times New Roman'; font-size:11pt">At a time of great economic challenge</span><span style="font-family:'Times New Roman'; font-size:11pt">, we were pleased to see that </span><span style="font-family:'Times New Roman'; font-size:11pt">investment in science and research was maintained, and particularly welcomed the </span><span style="font-family:'Times New Roman'; font-size:11pt">Government’s long-term commitment to provide more stable capital funding for science</span><span style="font-family:'Times New Roman'; font-size:11pt"> and its backing of the Charity Research Support Fund</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal; line-height:12pt; margin:0pt 0pt 12pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Specific </span><span style="font-family:'Times New Roman'; font-size:11pt">details of departmental allocations have not yet been announced. We will continue to work with BIS and other</span><span style="font-family:'Times New Roman'; font-size:11pt"> departments as the</span><span style="font-family:'Times New Roman'; font-size:11pt">se</span><span style="font-family:'Times New Roman'; font-size:11pt"> detail</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt"> are worked through.  </span></li></ol><p style="line-height:12pt; margin:0pt 0pt 12pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Potential future inquiries on UK R&amp;D funding</span></p><ol start="16" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal; line-height:12pt; margin:0pt 0pt 12pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Research</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">and development clusters provide a crucial mechanism to facilitate collaboration, promote knowledge sharing and accelerate innovation. There is an opportunity to examine progress in this area, consider where and how </span><span style="font-family:'Times New Roman'; font-size:11pt">UK </span><span style="font-family:'Times New Roman'; font-size:11pt">clusters might develop</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> and assess if</span><span style="font-family:'Times New Roman'; font-size:11pt"> there is sufficient</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt">funding for initial set up and operational costs.</span></li></ol><p style="line-height:12pt; margin:0pt 0pt 12pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">August 2013</span></p><p style="margin:0pt"><span style="font-family:'Arial (W1)'; font-size:11pt">&#xa0;</span></p></div><hr style="width:33%; height:1px; text-align:left" /><p style="margin:0pt"><a name="_ftn1"></a><a href="#_ftnref1">[1]</a><span style="font-family:Arial; font-size:10pt"> </span><span style="font-family:Arial; font-size:10pt">Wellcome</span><span style="font-family:Arial; font-size:10pt"> Trust, Medical Research Council and Academy of Medical Sciences</span><span style="font-family:Arial; font-size:10pt"> </span><span style="font-family:Arial; font-size:10pt; font-style:italic">Medical Research: What's it worth?</span><span style="font-family:Arial; font-size:10pt"> (2008) </span><span style="font-family:Arial; font-size:10pt">http://www.wellcome.ac.uk/About-us/Publications</span><span style="font-family:Arial; font-size:10pt">/Reports/Biomedical-science/WTX052113.htm</span></p><p style="margin:0pt"><a name="_ftn2"></a><a href="#_ftnref2">[2]</a><span style="font-family:Arial; font-size:10pt"> This data was gathered by a system called Researchfish which collects information about the outputs and outcomes of MRC research that have arisen since 2006.</span></p><p style="margin:0pt"><a name="_ftn3"></a><a href="#_ftnref3">[3]</a><span style="font-family:Arial; font-size:10pt"> Research Councils UK</span><span style="font-family:Arial; font-size:10pt"> </span><span style="font-family:Arial; font-size:10pt; font-style:italic">Investing for growth: Capita</span><span style="font-family:Arial; font-size:10pt; font-style:italic">l Infrastructure for the 21st Century</span><span style="font-family:Arial; font-size:10pt"> (2012) </span><span style="font-family:Arial; font-size:10pt">http://www.rcuk.ac.uk/documents/publications/RCUKFrameworkforCapitalInvestment2012.pdf</span></p></body></html>